Sector News

Takeda feels the sting of NICE's CDF takeover

August 12, 2016
Life sciences

Cancer drug makers have worried about the future of their products in England since its cost watchdog announced would take the reins of the Cancer Drugs Fund. Now, an appraisal of Takeda’s Adcetris shows they may have had good reason to.

The National Institute for Health and Care Excellence (NICE) said Wednesday in draft guidance that it wouldn’t recommend the med for the treatment of refractory systemic anaplastic lymphoma or relapsed or refractory CD30+ Hodgkin’s lymphoma, citing “immature and limited” evidence of the med’s clinical effectiveness.

It also pointed to the med’s price–Adcetris can cost between £69,000 and £87,000 per patient per course–and noted that the agency didn’t have the evidence needed to show that Adcetris represented a good value for that kind of money.

“We understand that this preliminary decision will be disappointing to patients who could be eligible for treatment,” Carole Longson, director of NICE’s Center for Health Technology Evaluation, said in a statement. “But we need to make sure that the drugs and treatments we look at will benefit patients and be a cost effective use of NHS resources.”

While the guidance won’t affect patients who are already on the drug–their treatment can continue without change to the funding arrangements that are already in place–if it holds, it could affect sales of Adcetris moving forward.

Even so, Takeda chose not to put forward a case for the product’s inclusion in the new CDF. That’s because of Adcetris’ tiny patient population–it sees about 50 to 60 eligible patients per year. The Japanese pharma was unclear on what further information it could gather on the drug through data collection going forward, it told NICE.

Pharma hasn’t been shy about sharing its opinions on NICE’s move to take over the beleaguered fund, which provided funding for several therapies the watchdogs deemed too pricey for routine NHS use. The head of global oncology for Eisai–whose Lenvima was axed from CDF’s covered list–said the switch creates “an utterly disgraceful situation,” while Roche recently argued that NICE’s methodology perpetuates “ongoing anxiety around the availability of existing and new cancer medicines” for patients.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.